Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteersOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study compared the gut bacterial communities of people with colorectal cancer against those of healthy people. Researchers sequenced fecal bacterial DNA to see whether cancer patients carry a structurally different microbiota. They profiled the V3 region of the 16S ribosomal RNA gene using 454 pyrosequencing. They then used statistical methods to find which bacterial groups separated the two populations.
Who was studied?
The cohort was 46 patients with colorectal cancer and 56 healthy volunteers, all providing fecal samples. Bacterial DNA from stool was sequenced and compared between the two groups. The analysis rested on fecal 16S sequencing rather than tissue biopsies. This captures the community living in the gut lumen.
What were the most important findings?
The gut microbiota of cancer patients was structurally distinct from that of healthy volunteers, confirmed by principal component and UniFrac analyses. Forty-eight bacterial groups drove this separation. Eleven groups from Enterococcus, Escherichia/Shigella, Klebsiella, Streptococcus and Peptostreptococcus were more abundant in cancer patients. One group related to Bacteroides fragilis was also enriched. Butyrate-producing bacteria, including five groups of Roseburia and other Lachnospiraceae, were reduced in patients. Quantitative PCR confirmed fewer butyryl-CoA transferase genes in cancer patients (P<0.01).
What are the greatest implications of this study?
The findings suggest colorectal cancer is accompanied by a specific imbalance: more opportunistic pathogens and fewer protective butyrate producers. Butyrate normally nourishes colon cells and supports the gut barrier. This structural signature could help clarify how gut bacteria contribute to cancer risk. It also points toward stool-based bacterial profiles as a possible avenue for research into detection and prevention.